These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

592 related articles for article (PubMed ID: 33272325)

  • 1. Treatment of pseudobulbar affect (PBA) in a patient with a history of traumatic brain injury, partial brain resection, and brainstem stroke: a case report.
    Young FG; Nguyen D
    J Med Case Rep; 2020 Dec; 14(1):235. PubMed ID: 33272325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dextromethorphan/quinidine for the treatment of pseudobulbar affect.
    Patatanian E; Casselman J
    Consult Pharm; 2014 Apr; 29(4):264-9. PubMed ID: 24704895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Approach of a High Functioning Individual With Traumatic Brain Injury and Subsequent Emotional Volatility With Features of Pathological Laughter and Crying With Dextromethorphan/Quinidine.
    Garcia-Baran D; Johnson TM; Wagner J; Shen J; Geers M
    Medicine (Baltimore); 2016 Mar; 95(12):e2886. PubMed ID: 27015166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dextromethorphan/quinidine sulfate for pseudobulbar affect.
    Rosen H
    Drugs Today (Barc); 2008 Sep; 44(9):661-8. PubMed ID: 19137121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury.
    Hammond FM; Alexander DN; Cutler AJ; D'Amico S; Doody RS; Sauve W; Zorowitz RD; Davis CS; Shin P; Ledon F; Yonan C; Formella AE; Siffert J
    BMC Neurol; 2016 Jun; 16():89. PubMed ID: 27276999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dextromethorphan/quinidine: in pseudobulbar affect.
    Garnock-Jones KP
    CNS Drugs; 2011 May; 25(5):435-45. PubMed ID: 21476614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions.
    Pattee GL; Wymer JP; Lomen-Hoerth C; Appel SH; Formella AE; Pope LE
    Curr Med Res Opin; 2014 Nov; 30(11):2255-65. PubMed ID: 25062507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dextromethorphan/quinidine: a review of its use in adults with pseudobulbar affect.
    Yang LP; Deeks ED
    Drugs; 2015 Jan; 75(1):83-90. PubMed ID: 25420446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crying and suicidal, but not depressed. Pseudobulbar affect in multiple sclerosis successfully treated with valproic acid: Case report and literature review.
    Johnson B; Nichols S
    Palliat Support Care; 2015 Dec; 13(6):1797-801. PubMed ID: 24916672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pseudobulbar affect in multiple sclerosis: toward the development of innovative therapeutic strategies.
    Miller A
    J Neurol Sci; 2006 Jun; 245(1-2):153-9. PubMed ID: 16674978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic use of dextromethorphan: key learnings from treatment of pseudobulbar affect.
    Miller A; Panitch H
    J Neurol Sci; 2007 Aug; 259(1-2):67-73. PubMed ID: 17433820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current concepts in the pharmacotherapy of pseudobulbar affect.
    Pioro EP
    Drugs; 2011 Jun; 71(9):1193-207. PubMed ID: 21711063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results.
    Doody RS; D'Amico S; Cutler AJ; Davis CS; Shin P; Ledon F; Yonan C; Siffert J
    CNS Spectr; 2016 Dec; 21(6):450-459. PubMed ID: 26471212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Compounded Dextromethorphan-Quinidine Suspension for Pseudobulbar Affect in Hospice Patients.
    Wahler RG; Reiman AT; Schrader JV
    J Palliat Med; 2017 Mar; 20(3):294-297. PubMed ID: 27997281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Among Study Participants With Traumatic Brain Injury: Results From the PRISM-II Open Label Study.
    Hammond FM; Sauve W; Ledon F; Davis C; Formella AE
    PM R; 2018 Oct; 10(10):993-1003. PubMed ID: 29477412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pseudobulbar affect: prevalence and management.
    Ahmed A; Simmons Z
    Ther Clin Risk Manag; 2013; 9():483-9. PubMed ID: 24348042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis.
    Panitch HS; Thisted RA; Smith RA; Wynn DR; Wymer JP; Achiron A; Vollmer TL; Mandler RN; Dietrich DW; Fletcher M; Pope LE; Berg JE; Miller A;
    Ann Neurol; 2006 May; 59(5):780-7. PubMed ID: 16634036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of pseudobulbar affect in a mixed neurodegenerative disorder with compounded quinidine capsules and dextromethorphan cough syrup.
    Villeneuve Y; Cruz-Santiago D; Masson H; Clerc D
    SAGE Open Med Case Rep; 2020; 8():2050313X20921076. PubMed ID: 32547756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The causes and treatment of pseudobulbar affect in ischemic stroke.
    Balakrishnan P; Rosen H
    Curr Treat Options Cardiovasc Med; 2008 Jun; 10(3):216-22. PubMed ID: 18582410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments.
    Miller A; Pratt H; Schiffer RB
    Expert Rev Neurother; 2011 Jul; 11(7):1077-88. PubMed ID: 21539437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.